Table 1.

Data summary (N = 4,343)

Parameter		Description*
Age at surgery		46 (± 12); 44 (37–54)
Type of uterine/cervical procedure	Conization	281 (6.5%)
	Radical hysterectomy	3,480 (80.2%)
	Radical parametrectomy	10 (0.2%)
	Radical trachelectomy	146 (3.4%)
	Simple hysterectomy	398 (9.2%)
	Trachelectomy	25 (0.6%)
	Not available (% of total)	3 (0.1%)
Type of parametrial resection	A	702 (16.9%)
	B	774 (18.6%)
	C1	1,742 (41.9%)
	C2	935 (22.5%)
	Not available (% of total)	190 (4.4%)
Surgical approach	Open	2,578 (59.5%)
	Laparoscopic	964 (22.2%)
	Robotic	428 (9.9%)
	Vaginal	219 (5.1%)
	Combined	146 (3.4%)
	Not available (% of total)	8 (0.2%)
Neoadjuvant therapy	No	4,164 (95.9%)
	Yes	179 (4.1%)
Sentinel lymph node biopsy performed (including ultrastaging)	No	3,342 (77.0%)
	Yes	1,001 (23.0%)
Pelvic lymphadenectomy performed	No	567 (13.1%)
	Yes	3,776 (86.9%)
Paraaortic lymphadenectomy performed	No	3,655 (84.2%)
	Yes	688 (15.8%)
Number of pelvic LN retrieved	(if > 0, n = 3,771)	25 (± 13); 23 (16–32)
Number of paraaortic LN retrieved	(if > 0, n = 632)	11 (± 8); 9 (5–14)
Number of positive pelvic LN	(if > 0, n = 643)	3 (± 3); 2 (1–3)
Number of positive paraaortic LN	(if > 0, n = 50)	5 (± 7); 2 (1–6)
Number of positive pelvic + paraaortic LN	(if > 0, n = 650)	3 (± 5); 2 (1–3)
Largest type of metastasis in LN (if number of positive LN > 0; n = 650)	Isolated tumour cells	27 (4.2%)
	Micrometastasis	89 (13.7%)
	Macrometastasis	534 (82.2%)
Pathologic T stage (pT)	1a1	550 (12.7%)
	1a2	421 (9.7%)
	1b1	2,709 (62.4%)
	1b2	321 (7.4%)
	2a1	155 (3.6%)
	2a2	39 (0.9%)
	2b	148 (3.4%)
Maximal pathologic tumour diameter	< 0.5 cm	711 (16.4%)
	0.5–1.99 cm	1,723 (39.7%)
	2–3.99 cm	1,349 (31.1%)
	≥ 4 cm	560 (12.9%)
Tumour histotype	Adenocancer	1,072 (24.7%)
	Adenosquamous	206 (4.8%)
	Neuroendocrine	43 (1.0%)
	Squamous	2,966 (68.4%)
	Other	49 (1.2%)
	Not available (% of total)	7 (0.2%)
Grade	1	599 (19.1%)
	2	1,628 (51.8%)
	3	917 (29.2%)
	Not available (% of total)	1,199 (27.6%)
LVSI	No	1,949 (55.6%)
	Yes	1,556 (44.4%)
	Not available (% of total)	838 (19.3%)
Adjuvant therapy	No	2,821 (65.0%)
	Yes	1,522 (35.0%)
Adjuvant therapy type (N = 1,522)	CRT	743 (48.8%)
	CT	68 (4.5%)
	NACT/RT and CT/outback	7 (0.5%)
	RT	704 (46.3%)
Cervical cancer recurrence	No	3,815 (87.8%)
	Yes	528 (12.2%)
Recurrence type (if recurrence = yes; n = 528)	Isolated	322 (61.9%)
	Multiple	198 (38.1%)
	Not available (% of n)	8 (1.5%)
Recurrence localization (if recurrence = yes; n = 528)	Pelvic	240 (46.3%)
	Distant	149 (28.8%)
	Combined	129 (24.9%)
	Not available (% of n)	10 (1.9%)
Recurrence diagnosis (if recurrence = yes; n = 528)	Follow-up visit	338 (72.7%)
	Unscheduled	127 (27.3%)
	Not available (% of n)	63 (11.9%)
Symptoms at recurrence (if recurrence = yes; n = 528)	Asymptomatic	189 (40.9%)
	Symptomatic	273 (59.1%)
	Not available (% of n)	66 (12.5%)
Recurrence treatment modality (if recurrence = yes; n = 528)	CRT	115 (24.0%)
	CT	180 (37.6%)
	RT	43 (9.0%)
	Surgery	37 (7.7%)
	Surgery + RT/CRT/CT	77 (16.1%)
	No treatment	23 (4.8%)
	Not available (% of n)	43 (10.1%)
Disease status at last FU visit	Alive with disease	144 (3.3%)
	Died of other cause	46 (1.1%)
	Died of disease	251 (5.8%)
	No evidence of disease	3,902 (89.8%)

^*Categorical variables are described by absolute and relative frequencies (% are based on available data only), mean (± SD) and median (25^th–75^th percentile) are shown for continuous variables.

CRT: chemoradiotherapy; CT: chemotherapy; LN: lymph node; NACT: neoadjuvant chemotherapy; RT: radiotherapy.